Rein Therapeutics, Inc. (RNTX): debt financing — Rein Therapeutics enters up to $21M financing with Yorkville via PPA and SEPA

Rein Therapeutics, Inc.

Pre-Paid Advance Agreement: up to $6M; initial $1M advance at 95% net ($0.95M); 8% annual interest rising to 18% on default.
Standby Equity Purchase Agreement: up to $15M over 36 months; shares sold at 96% of lowest 3-day VWAP.
Floor price set at $0.28 per share; Yorkville may require share issuance at lower of 115% of VWAP or 95% of lowest 7-day VWAP.
Commitment fee of $300k paid as 213,099 shares plus $25k structuring fees; Exchange Cap limited to 19.9% of outstanding shares.
Proceeds used for general corporate purposes; shares registered on Form S-3 (File No. 333-287342).

item 1.01 item 2.03 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Rein Therapeutics, Inc. incurred credit facility of up to $6.0 million with YA II PN, Ltd. at 8%.

Instrument: credit facility
Principal: up to $6.0 million
Counterparty: YA II PN, Ltd.
Rate: 8%
Event: incurrence

Exact text from the filing

(the “Company”) entered into a Pre-Paid Advance Agreement (the “PPA”) with YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Yorkville”). In accordance with the terms of the PPA, the Company may request pre-paid advances of up to $6.0 million from Yorkville (each, a “Pre-Paid Advance”) over a 12-month period, subject to certain limitations and conditions set forth in the PPA.

View on SEC.gov

Browse all debt financings →

Rein Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-168830

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.